Recent developments
Corporate strategy shifts
Amid stable demand, the dsm-firmenich Q3 2025 update reported 2% organic sales growth and higher comparable Adjusted EBITDA. Full-year 2025 Adjusted EBITDA is guided around €2.3 billion, factoring a €90 million FX headwind and €50 million lower vitamin contributions in ANH. The company continues the ANH divestment for completion by Q4 2025 and had executed about 85% of its €1 billion buyback.
Amino acid logistics
Evonik leveraged a planned Antwerp shutdown to upgrade the logistics infrastructure for MetAMINO®, adding a new filling line and big bag storage to expand packaging to 1,000 kg big bags, 25 kg bags, and bulk. The redesigned 25 kg bag cuts CO2 by 20% versus the prior version. Global supply is supported by production hubs in Antwerp, Mobile, and Singapore, with capacity above 700,000 t/y.
Vitamin formulations advance
BASF expanded vitamin offerings with Lutavit® A/D3 1000/200 NXT, a microencapsulated blend manufactured in Ludwigshafen. The formulation targets stability in premixes and pellets, a standardized 5:1 A:D3 ratio, and an 18‑month shelf life, addressing convenience and performance requirements across species.
Plant-based additive developments
Functional, plant-based additives saw new launches. Evonik introduced BoruCare® Capsin for ruminants, a chili-derived, solvent-free, encapsulated ingredient to support nutrient status and heat stress management, slated for European availability in Q4 2025. In pet nutrition, BENEO demonstrated that faba bean protein concentrate can replace spray dried animal blood plasma in wet applications, citing cost benefits, strong binding, and local sourcing.